Read more
3:08 PM · 13 July 2020

Quest Diagnostics stock rose 5.4% after its preliminary Q2 results

Quest
Stocks
DGX.US, Quest Diagnostics Inc
-
-
Quest Diagnostics (DGX.US) reported preliminary second-quarter revenue above analyst expectations, due largely to growing demand for Covid-19 tests. The medical lab operator expects second-quarter revenue of about $1.83 billion, a decline of about 6% from the year-earlier period but well ahead of the $1.53 billion FactSet consensus. Company expects per-share earnings of $1.33 to $1.36, compared with $1.51 a year ago. Adjusted EPS is expected to range from $1.39 to $1.42, compared with $1.73 in 2019 and a the FactSet estimates of 16 cents. Quest Diagnostics will report second-quarter earnings on July 23.
Quest Diagnostics (DGX.US)  has been trading in an sideways move since end of April. The price bounced off the lower limit of consolidation range at the end of June. Today, one can see that the upward move is being continued after US open. Currently stock is approaching the key resistance area at $123.57 per share. If sellers manage to halt declines here, the downward move into $102.92 per share is possible. Source: xStation5
14 November 2025, 6:28 PM

Alibaba sell-off extends amid White House national security concerns📌

14 November 2025, 4:42 PM

US Earnings Season Summary 🗽What the Latest FactSet Data Shows

14 November 2025, 4:06 PM

US Open: US100 initiates rebound attempt 🗽Micron shares near ATH📈

14 November 2025, 12:56 PM

Micron Surges on Record DRAM Pricing

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits